Alfred Asante‐Korang

In pediatric patients who undergo heart transplantation, severe immune‐mediated bowel disease has been reported. Management is complex, and there are little data discussing the use of basiliximab for immune‐mediated bowel disease. This case report discusses a pediatric patient who developed immune‐mediated bowel disease following heart transplantation and was successfully managed with basiliximab.